• Unveiling of Vitiligo Visual Algorithm (VVA), an AI-driven assessment tool
• Expanded CLINUVEL pavilion to engage dermatology community
• Satellite symposia provide real-time feedback on CLINUVEL's programs

CLINUVEL Pharmaceuticals is revealing its expansive program for the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver. The company's work features across academic presentations, exhibitions, and events, with a focus on the development of afamelanotide to treat vitiligo and SCENESSE® (afamelanotide), the only FDA-approved treatment for patients with the rare disorder erythropoietic protoporphyria (EPP). CLINUVEL is particularly excited to be unveiling the Vitiligo Visual Algorithm (VVA), a novel, AI-driven tool developed in-house to objectively assess pigmentation using standardized clinical photographs and track patient treatment progress over time. The company's Pavilion of Photomedicine has also been completely reimagined for the 2026 AAD Meeting to take attendees on an immersive journey through CLINUVEL's scientific heritage, patient focus, and future vision. Additionally, CLINUVEL has supported three satellite symposia on 26 March as part of its ongoing commitment to academic engagement, providing valuable real-time feedback on its programs.

CLINUVEL is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The company's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation, and acute or life-threatening conditions who lack alternatives.